Dance Biopharm is focused on the development of inhaled insulin products to treat diabetes patients worldwide. The company began operations in 2010 led by Dr. John Patton, who has over 20 years of experience in the development of inhaled insulin. The Dance team consists of experts in all aspects of inhaled insulin development, and we are dedicated to creating a new generation of products that make inhaled insulin more compelling than ever.
Dance-501 is an investigational drug-device combination under development for treatment of diabetes with the intent to eliminate the need for injections for mealtime insulin. Dance-501 includes a liquid formulation of natural human insulin and a small silent handheld electronic aerosol device, intended to deliver the patient’s individualized dose of insulin in 1-3 breaths at mealtime. dance-501 technology allows for efficient insulin delivery and the potential to make inhaled insulin easy and economical.
Data Connectivity for Better Management of Diabetes Treatment SAN FRANCISCO, Dec. 4, 2017 /PRNewswire/ -- Dance Biopharm Holdings Inc. ("Dance"),More News